Fennec Pharmaceuticals (FENC) Interest Expenses (2014 - 2025)
Fennec Pharmaceuticals posted quarterly Interest Expenses of $308000.0 for Q4 2025, down 68.12% year-on-year from $966000.0 in Q4 2024, and down 47.44% on a QoQ basis from $586000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 7 years of Interest Expenses data on file, last reported at $308000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses fell 68.12% year-over-year to $308000.0; the trailing twelve-month figure through Dec 2025 stood at $2.1 million (down 48.88% YoY), and the FY2025 full-year result was $2.1 million, down 48.88% from the prior year.
- Interest Expenses for Q4 2025 stood at $308000.0, down from $586000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.0 million in Q2 2024 and bottomed at $4000.0 in Q1 2021.
- The 5-year median for Interest Expenses is $593000.0 (2025), against an average of $532550.0.
- The widest annual swing landed in 2022, when Interest Expenses jumped 1350.0%; it then plunged 68.12% in 2025.
- A 5-year view of Interest Expenses shows it stood at $62000.0 in 2021, then jumped by 1100.0% to $744000.0 in 2022, then climbed by 22.98% to $915000.0 in 2023, then advanced by 5.57% to $966000.0 in 2024, then slumped by 68.12% to $308000.0 in 2025.
- The last three Interest Expenses figures came in at $308000.0 (Q4 2025), $586000.0 (Q3 2025), and $594000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 308,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 308,000.00 |
| Dec 31, 2025 | 308,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Mar 31, 2025 | 592,000.00 |
| Mar 31, 2025 | 592,000.00 |
| Dec 31, 2024 | 966,000.00 |
| Dec 31, 2024 | 966,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 915,000.00 |
| Dec 31, 2023 | 915,000.00 |
| Sep 30, 2023 | 856,000.00 |
| Sep 30, 2023 | 856,000.00 |
| Jun 30, 2023 | 825,000.00 |
| Jun 30, 2023 | 825,000.00 |
| Mar 31, 2023 | 798,000.00 |
| Mar 31, 2023 | 798,000.00 |
| Dec 31, 2022 | 744,000.00 |
| Dec 31, 2022 | 744,000.00 |
| Sep 30, 2022 | 119,000.00 |
| Sep 30, 2022 | 119,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Dec 31, 2021 | 62,000.00 |
| Dec 31, 2021 | 62,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Jun 30, 2015 | 10,000.00 |
| Jun 30, 2015 | 10,000.00 |
| Jun 30, 2014 | 4,000.00 |
| Jun 30, 2014 | 4,000.00 |